This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that
Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the NewsMakers in the Biotech Industry 2013 Conference in
New York City next week. The presentation is scheduled for
Friday, September 27, 2013 at
2:00 p.m. EDT.
The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at
About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.
Contact:Jennifer Cook WilliamsCook Williams Communications, Inc.Investor and Media Relations360.668.3701
SOURCE Omeros Corporation